APO Research

APO RESEARCH · REPORT

TB Vaccines

Selected research

Market Outlook & Growth Opportunities

Global TB Vaccines Market Outlook and Growth Opportunities 2026

Market perspective

The global TB Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for TB Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for TB Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for TB Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the TB Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the TB Vaccines market include China National Biotec Group, Sanofi Pasteur, Merck & Co.,Inc, Statens Serum Institut, Serum Institute, Japan BCG Laboratory, InterVax Ltd, India Pvt. Ltd and GreenSignal, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global TB Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of TB Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents TB Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the TB Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

TB Vaccines Segment by Company

China National Biotec Group

Sanofi Pasteur

Merck & Co.,Inc

Statens Serum Institut

Serum Institute

Japan BCG Laboratory

InterVax Ltd

India Pvt. Ltd

GreenSignal

Bio Pharma Limited

TB Vaccines Segment by Type

Immunotherapeutic Vaccines

Booster Vaccines

Others

TB Vaccines Segment by Application

Private Clinics

Research Institutes

Hospitals

TB Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global TB Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions TB Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify TB Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze TB Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TB Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TB Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TB Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the TB Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global TB Vaccines industry.

Chapter 3: Detailed analysis of TB Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of TB Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of TB Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. TB Vaccines Industry Trends Table 2. TB Vaccines Industry Drivers Table 3. TB Vaccines Industry Opportunities and Challenges Table 4. TB Vaccines Industry Restraints Table 5. Global TB Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global TB Vaccines Revenue Share by Company (2021-2026) Table 7. Global TB Vaccines Sales Volume by Company (W Units) & (2021-2026) Table 8. Global TB Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global TB Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global TB Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global TB Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global TB Vaccines Company, Product Type & Application Table 13. Global TB Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global TB Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immunotherapeutic Vaccines Table 18. Significant Companies of Booster Vaccines Table 19. Significant Companies of Others Table 20. Global TB Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global TB Vaccines Sales Volume by Type (2021-2026) & (W Units) Table 22. Global TB Vaccines Sales Volume by Type (2027-2032) & (W Units) Table 23. Global TB Vaccines Sales Volume Share by Type (2021-2026) Table 24. Global TB Vaccines Sales Volume Share by Type (2027-2032) Table 25. Global TB Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global TB Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global TB Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global TB Vaccines Sales Value Share by Type (2021-2026) Table 29. Global TB Vaccines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Private Clinics Table 31. Significant Companies of Research Institutes Table 32. Significant Companies of Hospitals Table 33. Global TB Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global TB Vaccines Sales Volume by Application (2021-2026) & (W Units) Table 35. Global TB Vaccines Sales Volume by Application (2027-2032) & (W Units) Table 36. Global TB Vaccines Sales Volume Share by Application (2021-2026) Table 37. Global TB Vaccines Sales Volume Share by Application (2027-2032) Table 38. Global TB Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global TB Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global TB Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global TB Vaccines Sales Value Share by Application (2021-2026) Table 42. Global TB Vaccines Sales Value Share by Application (2027-2032) Table 43. Global TB Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global TB Vaccines Sales by Region (2021-2026) & (W Units) Table 45. Global TB Vaccines Sales Market Share by Region (2021-2026) Table 46. Global TB Vaccines Sales by Region (2027-2032) & (W Units) Table 47. Global TB Vaccines Sales Market Share by Region (2027-2032) Table 48. Global TB Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global TB Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global TB Vaccines Sales Value Share by Region (2021-2026) Table 51. Global TB Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global TB Vaccines Sales Value Share by Region (2027-2032) Table 53. Global TB Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global TB Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global TB Vaccines Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Global TB Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global TB Vaccines Sales by Country (2021-2026) & (W Units) Table 58. Global TB Vaccines Sales Market Share by Country (2021-2026) Table 59. Global TB Vaccines Sales by Country (2027-2032) & (W Units) Table 60. Global TB Vaccines Sales Market Share by Country (2027-2032) Table 61. Global TB Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global TB Vaccines Sales Value Market Share by Country (2021-2026) Table 63. Global TB Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global TB Vaccines Sales Value Market Share by Country (2027-2032) Table 65. China National Biotec Group Company Information Table 66. China National Biotec Group Business Overview Table 67. China National Biotec Group TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. China National Biotec Group TB Vaccines Product Portfolio Table 69. China National Biotec Group Recent Development Table 70. Sanofi Pasteur Company Information Table 71. Sanofi Pasteur Business Overview Table 72. Sanofi Pasteur TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Sanofi Pasteur TB Vaccines Product Portfolio Table 74. Sanofi Pasteur Recent Development Table 75. Merck & Co.,Inc Company Information Table 76. Merck & Co.,Inc Business Overview Table 77. Merck & Co.,Inc TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck & Co.,Inc TB Vaccines Product Portfolio Table 79. Merck & Co.,Inc Recent Development Table 80. Statens Serum Institut Company Information Table 81. Statens Serum Institut Business Overview Table 82. Statens Serum Institut TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Statens Serum Institut TB Vaccines Product Portfolio Table 84. Statens Serum Institut Recent Development Table 85. Serum Institute Company Information Table 86. Serum Institute Business Overview Table 87. Serum Institute TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Serum Institute TB Vaccines Product Portfolio Table 89. Serum Institute Recent Development Table 90. Japan BCG Laboratory Company Information Table 91. Japan BCG Laboratory Business Overview Table 92. Japan BCG Laboratory TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Japan BCG Laboratory TB Vaccines Product Portfolio Table 94. Japan BCG Laboratory Recent Development Table 95. InterVax Ltd Company Information Table 96. InterVax Ltd Business Overview Table 97. InterVax Ltd TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. InterVax Ltd TB Vaccines Product Portfolio Table 99. InterVax Ltd Recent Development Table 100. India Pvt. Ltd Company Information Table 101. India Pvt. Ltd Business Overview Table 102. India Pvt. Ltd TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. India Pvt. Ltd TB Vaccines Product Portfolio Table 104. India Pvt. Ltd Recent Development Table 105. GreenSignal Company Information Table 106. GreenSignal Business Overview Table 107. GreenSignal TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. GreenSignal TB Vaccines Product Portfolio Table 109. GreenSignal Recent Development Table 110. Bio Pharma Limited Company Information Table 111. Bio Pharma Limited Business Overview Table 112. Bio Pharma Limited TB Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Bio Pharma Limited TB Vaccines Product Portfolio Table 114. Bio Pharma Limited Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. TB Vaccines Distributors List Table 118. TB Vaccines Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. TB Vaccines Product Image Figure 2. Global TB Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TB Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global TB Vaccines Sales (2021-2032) & (W Units) Figure 5. Global TB Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global TB Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immunotherapeutic Vaccines Image Figure 10. Booster Vaccines Image Figure 11. Others Image Figure 12. Global TB Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global TB Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global TB Vaccines Sales Volume Share by Type (2021-2032) Figure 15. Global TB Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global TB Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global TB Vaccines Sales Value Share by Type (2021-2032) Figure 18. Private Clinics Image Figure 19. Research Institutes Image Figure 20. Hospitals Image Figure 21. Global TB Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global TB Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global TB Vaccines Sales Volume Share by Application (2021-2032) Figure 24. Global TB Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global TB Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global TB Vaccines Sales Value Share by Application (2021-2032) Figure 27. Global TB Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 28. Global TB Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global TB Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global TB Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America TB Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. North America TB Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe TB Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe TB Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific TB Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific TB Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America TB Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. South America TB Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa TB Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa TB Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt TB Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt TB Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt TB Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. TB Vaccines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. TB Vaccines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapeutic Vaccines
  • Booster Vaccines
  • Others
Applications
  • Private Clinics
  • Research Institutes
  • Hospitals
Companies covered
  • China National Biotec Group
  • Sanofi Pasteur
  • Merck & Co.,Inc
  • Statens Serum Institut
  • Serum Institute
  • Japan BCG Laboratory
  • InterVax Ltd
  • India Pvt. Ltd
  • GreenSignal
  • Bio Pharma Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global TB Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global TB Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global TB Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 TB Vaccines Market Dynamics
  1. 2.1 TB Vaccines Industry Trends
  2. 2.2 TB Vaccines Industry Drivers
  3. 2.3 TB Vaccines Industry Opportunities and Challenges
  4. 2.4 TB Vaccines Industry Restraints
3 TB Vaccines Market by Company
  1. 3.1 Global TB Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global TB Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global TB Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global TB Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global TB Vaccines Company Ranking (2024-2026)
  6. 3.6 Global TB Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global TB Vaccines Company Product Type and Application
  8. 3.8 Global TB Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global TB Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 TB Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 TB Vaccines Market by Type
  1. 4.1 TB Vaccines Type Introduction
  2. 4.1.1 Immunotherapeutic Vaccines
  3. 4.1.2 Booster Vaccines
  4. 4.1.3 Others
  5. 4.2 Global TB Vaccines Sales Volume by Type
  6. 4.2.1 Global TB Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global TB Vaccines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global TB Vaccines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global TB Vaccines Sales Value by Type
  10. 4.3.1 Global TB Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global TB Vaccines Sales Value by Type (2021-2032)
  12. 4.3.3 Global TB Vaccines Sales Value Share by Type (2021-2032)
5 TB Vaccines Market by Application
  1. 5.1 TB Vaccines Application Introduction
  2. 5.1.1 Private Clinics
  3. 5.1.2 Research Institutes
  4. 5.1.3 Hospitals
  5. 5.2 Global TB Vaccines Sales Volume by Application
  6. 5.2.1 Global TB Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global TB Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global TB Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global TB Vaccines Sales Value by Application
  10. 5.3.1 Global TB Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global TB Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global TB Vaccines Sales Value Share by Application (2021-2032)
6 TB Vaccines Regional Sales and Value Analysis
  1. 6.1 Global TB Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global TB Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global TB Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global TB Vaccines Sales by Region (2027-2032)
  5. 6.3 Global TB Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global TB Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global TB Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global TB Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global TB Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America TB Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America TB Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe TB Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe TB Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific TB Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific TB Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America TB Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America TB Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa TB Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa TB Vaccines Sales Value Share by Country, 2025 VS 2032
7 TB Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global TB Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global TB Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global TB Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global TB Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global TB Vaccines Sales by Country (2027-2032)
  6. 7.4 Global TB Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global TB Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global TB Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA TB Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA TB Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA TB Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada TB Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada TB Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada TB Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico TB Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico TB Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico TB Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany TB Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany TB Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany TB Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France TB Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France TB Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France TB Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. TB Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. TB Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. TB Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy TB Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy TB Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy TB Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain TB Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain TB Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain TB Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia TB Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia TB Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia TB Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands TB Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands TB Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands TB Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries TB Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries TB Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries TB Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China TB Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China TB Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China TB Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan TB Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan TB Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan TB Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea TB Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea TB Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea TB Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India TB Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India TB Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India TB Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia TB Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia TB Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia TB Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia TB Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia TB Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia TB Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil TB Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil TB Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil TB Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina TB Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina TB Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina TB Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile TB Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile TB Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile TB Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia TB Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia TB Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia TB Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru TB Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru TB Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru TB Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia TB Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia TB Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia TB Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel TB Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel TB Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel TB Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE TB Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE TB Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE TB Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey TB Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey TB Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey TB Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran TB Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran TB Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran TB Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt TB Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt TB Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt TB Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China National Biotec Group
  2. 8.1.1 China National Biotec Group Company Information
  3. 8.1.2 China National Biotec Group Business Overview
  4. 8.1.3 China National Biotec Group TB Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 China National Biotec Group TB Vaccines Product Portfolio
  6. 8.1.5 China National Biotec Group Recent Developments
  7. 8.2 Sanofi Pasteur
  8. 8.2.1 Sanofi Pasteur Company Information
  9. 8.2.2 Sanofi Pasteur Business Overview
  10. 8.2.3 Sanofi Pasteur TB Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Pasteur TB Vaccines Product Portfolio
  12. 8.2.5 Sanofi Pasteur Recent Developments
  13. 8.3 Merck & Co.,Inc
  14. 8.3.1 Merck & Co.,Inc Company Information
  15. 8.3.2 Merck & Co.,Inc Business Overview
  16. 8.3.3 Merck & Co.,Inc TB Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co.,Inc TB Vaccines Product Portfolio
  18. 8.3.5 Merck & Co.,Inc Recent Developments
  19. 8.4 Statens Serum Institut
  20. 8.4.1 Statens Serum Institut Company Information
  21. 8.4.2 Statens Serum Institut Business Overview
  22. 8.4.3 Statens Serum Institut TB Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Statens Serum Institut TB Vaccines Product Portfolio
  24. 8.4.5 Statens Serum Institut Recent Developments
  25. 8.5 Serum Institute
  26. 8.5.1 Serum Institute Company Information
  27. 8.5.2 Serum Institute Business Overview
  28. 8.5.3 Serum Institute TB Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Serum Institute TB Vaccines Product Portfolio
  30. 8.5.5 Serum Institute Recent Developments
  31. 8.6 Japan BCG Laboratory
  32. 8.6.1 Japan BCG Laboratory Company Information
  33. 8.6.2 Japan BCG Laboratory Business Overview
  34. 8.6.3 Japan BCG Laboratory TB Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Japan BCG Laboratory TB Vaccines Product Portfolio
  36. 8.6.5 Japan BCG Laboratory Recent Developments
  37. 8.7 InterVax Ltd
  38. 8.7.1 InterVax Ltd Company Information
  39. 8.7.2 InterVax Ltd Business Overview
  40. 8.7.3 InterVax Ltd TB Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 InterVax Ltd TB Vaccines Product Portfolio
  42. 8.7.5 InterVax Ltd Recent Developments
  43. 8.8 India Pvt. Ltd
  44. 8.8.1 India Pvt. Ltd Company Information
  45. 8.8.2 India Pvt. Ltd Business Overview
  46. 8.8.3 India Pvt. Ltd TB Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 India Pvt. Ltd TB Vaccines Product Portfolio
  48. 8.8.5 India Pvt. Ltd Recent Developments
  49. 8.9 GreenSignal
  50. 8.9.1 GreenSignal Company Information
  51. 8.9.2 GreenSignal Business Overview
  52. 8.9.3 GreenSignal TB Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GreenSignal TB Vaccines Product Portfolio
  54. 8.9.5 GreenSignal Recent Developments
  55. 8.10 Bio Pharma Limited
  56. 8.10.1 Bio Pharma Limited Company Information
  57. 8.10.2 Bio Pharma Limited Business Overview
  58. 8.10.3 Bio Pharma Limited TB Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bio Pharma Limited TB Vaccines Product Portfolio
  60. 8.10.5 Bio Pharma Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 TB Vaccines Value Chain Analysis
  2. 9.1.1 TB Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 TB Vaccines Sales Mode & Process
  6. 9.2 TB Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 TB Vaccines Distributors
  9. 9.2.3 TB Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research